Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$13.00 USD
-0.27 (-2.03%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $13.01 +0.01 (0.08%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.00 USD
-0.27 (-2.03%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $13.01 +0.01 (0.08%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Zacks News
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 19.30% and 45.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Urogen Pharma (URGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 5% and 26.61%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
by Zacks Equity Research
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
by Zacks Equity Research
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data
by Zacks Equity Research
Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 3.23% and 24.34%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Stoke Therapeutics (STOK)
by Zacks Equity Research
Stoke Therapeutics (STOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Stoke Therapeutics, Inc. (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sage Therapeutics (SAGE) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Sage Therapeutics' (SAGE) earnings and revenues surpass estimates in the fourth quarter of 2023. Focus on newly launched PPD drug, Zurzuvae. Stock rise.
Alkermes' (ALKS) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Alkermes' (ALKS) earnings and revenues outpace estimates in the fourth quarter of 2023. Strong growth in proprietary products drives year-over-year revenues.
Will High Expenses Ail Pediatrix Medical's (MD) Q4 Earnings?
by Zacks Equity Research
Pediatrix Medical's (MD) Q4 results are likely to be hurt by an increase in practice salaries and benefits expense as well as softer patient volumes, partly offset by same-unit pricing growth.
Does Stoke Therapeutics, Inc. (STOK) Have the Potential to Rally 284.14% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Stoke Therapeutics, Inc. (STOK) points to a 284.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Stoke Therapeutics, Inc. (STOK) Stock Jumps 25.5%: Will It Continue to Soar?
by Zacks Equity Research
Stoke Therapeutics, Inc. (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
New Strong Buy Stocks for February 14th
by Zacks Equity Research
GLTO, LUMN, MORF, SFST and STOK have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.
Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 2.44% and 0.76%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results
by Zacks Equity Research
Amarin (AMRN) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also plans to initiate a share repurchase program of up to $50 million. Stock gains.
Wall Street Analysts Predict a 220.81% Upside in Stoke Therapeutics, Inc. (STOK): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 220.8% upside potential for Stoke Therapeutics, Inc. (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of -6.15% and 162.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Stoke Therapeutics, Inc. (STOK) Moves 7.7% Higher: Will This Strength Last?
by Zacks Equity Research
Stoke Therapeutics, Inc. (STOK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Stoke Therapeutics, Inc. (STOK) Surges 6.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Stoke Therapeutics, Inc. (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Should You Buy Stoke Therapeutics, Inc. (STOK) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
How Much Upside is Left in Stoke Therapeutics, Inc. (STOK)? Wall Street Analysts Think 102.91%
by Zacks Equity Research
The consensus price target hints at a 102.9% upside potential for Stoke Therapeutics, Inc. (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Analysts Estimate Synlogic, Inc. (SYBX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Synlogic, Inc. (SYBX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.